New cancer clinical trial: Study on MK-3475 Plus Chemotherapy Versus Chemotherapy Alone in Recurrent, Platinum-resistant Ovarian Cancer

Published on: May 28, 2018 at 12:00PM
Condition:   Ovarian Cancer
Interventions:   Drug: Pembrolizumab;   Drug: Gemcitabine;   Drug: Paclitaxel;   Drug: Liposomal Doxorubicin
Sponsor:   Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Not yet recruiting
https://ift.tt/2L75fd9